Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

Xilio Therapeutics, Inc. (NASDAQ:XLO – Get Free Report) was the recipient of a large decline in short interest in the month of March.As of March 15th, there was short interest totalling 575,500 ...

Silexion Therapeutics Corp. has announced an expanded development plan for its next-generation siRNA candidate SIL-204. The new dual-route strategy will integrate intratumoral and systemic ...

— We have everything you need: full data on over 700 000 bonds, stocks & ETFs; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & financial reports; ...

GRAND CAYMAN - Silexion Therapeutics Corp. (NASDAQ: SLXN), a micro-cap biotechnology firm with a market capitalization of $9.93 million focused on RNA interference (RNAi) therapies, has announced an ...

“Our expanded development plan reflects the strength of recent preclinical data and our commitment to addressing the complexities of KRAS-driven cancers,” said Ilan Hadar, Chairman and CEO of Silexion ...